How much funding has Accro Bioscience raised?

Accro Bioscience has raised $100.0M in total funding, most recently a Series C round.

Who are Accro Bioscience's investors?

Accro Bioscience's investors include OrbiMed, Hongtai Capital Holdings, Shenzhen Capital Group, TCG Crossover, LAV (Lilly Asia Ventures), Cenova Capital.

When was Accro Bioscience founded?

Accro Bioscience was founded in 2017.

Where is Accro Bioscience headquartered?

Accro Bioscience is headquartered in Suzhou, China.

What industry is Accro Bioscience in?

Accro Bioscience operates in Biotech.

How many employees does Accro Bioscience have?

Accro Bioscience has 11-50 employees.

Accro Bioscience

Innovative drugs for inflammation and autoimmune disease

Suzhou, China · Founded 2017 · $100.0M raised

Biotech

Headquarters: Suzhou
Employees: 11–50
Founded: 2017
Business Model: B2B

Website: accropeutics.com
Total Funding: $100.0M
Last Round: $50.0M Series CMay 2026
Rounds: 2

About

Accropeutics (Accro Bioscience) is a Suzhou, China-based clinical-stage biotech focused on inflammation, autoimmune diseases, and cancer. Its lead asset AC-101, a RIPK2 inhibitor, received FDA IND clearance for Phase II in moderate-to-severe ulcerative colitis. A secondary asset AC-201 targets TYK2/JAK1 for non-infectious uveitis. The company secured $12M in Series B Plus financing in March 2025.

Summary

Accro Bioscience is a Biotech company based in Suzhou, China, founded in 2017. It has raised $100.0M in total across 2 rounds, most recently a $50.0M Series C round in May 2026. Investors include OrbiMed, Hongtai Capital Holdings and Shenzhen Capital Group.